BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL

(1)
LUND, Sweden, Jan. 26, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment of the first patient in a Phase I/IIa, first-in-human study of BI-1808 as monotherapy and in combination with the anti-PD-1 therapy Keytruda
(pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). The first patient in the Phase I/IIa study has been enrolled in Denmark.
BI-1808 is the lead development candidate from a panel of TNFR2-specific antibodies that BioInvent has generated from its proprietary n-CoDeR

Related Keywords

Sweden ,Denmark ,Martin Welschof ,Mary Ann Chang ,Bioinvent International ,Prnewswire Bioinvent International Ab ,Ann Chang ,ஸ்வீடந் ,டென்மார்க் ,மேரி ஆண்டு சாங் ,ஆண்டு சாங் ,